Bookmark

Add to MyYahoo RSS

Gilead Sciences News

News on Gilead Sciences (Ticker: GILD) continually updated from thousands of sources around the net.

10 hrs ago | The Motley Fool

3 Reasons Gilead Science, Inc.'s Stock Could Rise

Here are three things that could send shares higher if they come to fruition. 1. Sales of Gilead's hepatitis C drugs don't drop Talk about a low bar for success.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Oncology

20 hrs ago | AmericanBankingNews.com

Recent Analysts' Ratings Updates for Gilead Sciences

A number of stock research firms have changed their ratings and price targets for Gilead Sciences during the last seven days: Gilead Sciences is now covered by analysts at Argus.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals

Yesterday | Foster's Daily Democrat

$1,000 Sovaldi now hepatitis treatment of choice

The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.

Comment?

Related Topix: Hepatitis, Medicine, Health, Biotech, Healthcare Industry, Startups, Gilead Sciences, Health Insurance, Medicaid

Mon Aug 18, 2014

GuruFocus.com

New Magic Formula Stocks From Joel Greenblatt: CBI, DAL, GILD, MNST, ROST, LUV

Hedge fund manager, the inventor of "Magic Formula" Joel Greenblatt just reported his second quarter portfolio at Gotham Asset Management, LLC. He reshuffled his portfolio dramatically during the quarter, and bought Chicago Bridge & Iron Company, Delta Air Lines Inc, Towers Watson & Co, Gilead Sciences Inc, Monster Beverage Corp, Teradata Corp, ... (more)

Comment?

Related Topix: Airlines, Delta Air Lines, Transportation, Construction, Industrial Machines, Chicago Bridge and Iron, Metals, Biotech, Medicine, Healthcare Industry, Monster Worldwide, Human Resources, Advertising, Ross Systems, Software

AmericanBankingNews.com

Insider Selling: Gilead Sciences CFO Unloads 33,556 Shares of Stock

Gilead Sciences CFO Robin L. Washington sold 33,556 shares of the company's stock on the open market in a transaction dated Thursday, August 14th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Investopedia

4 Large-Cap Healthcare Stocks To Watch

Healthcare has been one of the hottest sectors over the last year and continues to find new highs.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences

Forbes.com

UK Says Sovaldi Is Worth It. We Should Listen.

It's rare that I get to say this - but we can learn something from the United Kingdom.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Hepatitis, Health, Medicare

Sat Aug 16, 2014

Knoxville News Sentinel

David Moon: Breakthrough pill presents puzzle The U.S. Centers for...

The U.S. Centers for Disease Control and Prevention estimates there are 3.2 million Americans with chronic hepatitis C, 17,000 of whom will die this year as a result of the infection - a number that exceeds the annual deaths from HIV/AIDS in the U.S. Fortunately, Gilead Sciences produces a new breakthrough drug, Sovaldi, which has proved to cure 90 ... (more)

Comment?

Related Topix: Centers for Disease Control and Prevention, Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, US News, US Senate, Ron Wyden, Democrat, US Politics, Republican, Chuck Grassley, Sports

PR-inside.com

New Market Research Report: Pharmasset, Inc - Pharmaceuticals &...

The company is engaged in discovering, producing and commercializing medicines to treat viral infections.

Comment?

Related Topix: Pharmaceuticals, Pharmasset, Hepatitis, Medicine, Health, Biotech, Healthcare Industry, Startups, Gilead Sciences

Iol.co.za

Wall St ends mixed, recovers from Ukraine slide

US stocks ended mixed on Friday, paring an earlier selloff sparked by reports of Ukraine shelling a Russian armoured column.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Healthcare Industry

Fri Aug 15, 2014

AmericanBankingNews.com

Gilead Sciences Shares Gap Up After Analyst Upgrade

Gilead Sciences 's share price gapped up before the market opened on Friday after Cowen and Company raised their price target on the stock from $95.00 to $105.00, Analyst Ratings Net reports.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

SchaeffersResearch.com

Analyst Update: J C Penney Company Inc, Monster Beverage Corp, and Gilead Sciences, Inc.

However, J.P. Morgan Securities raised its price target on JCP to $11 from $9, representing an unusually bullish forecast for the stock.

Comment?

Related Topix: JC Penney, Biotech, Retail, Medicine, Healthcare Industry, Monster Worldwide, Startups, Gilead Sciences, Human Resources, Advertising, Day Trading, Financial Markets, Personal Finance

San Jose Mercury News

Biz Break: Applied Materials surges on post-earnings glow

Today: Shares in Santa Clara equipment maker Applied Materials get a boost after it reports big jump in profit, improved sales forecast.

Comment?

Related Topix: Semiconductors, Electronics, Applied Materials, Startups, MadFox, Break., Video Games, Santa Clara, CA, Santa Clara County, CA, Biotech, Medicine, Healthcare Industry, IGN Entertainment

Seeking Alpha

Why Gilead Is The Most Exciting Growth Opportunity In 2014

Investors are often deterred from investing in a stock when its price reaches an all-time high as it recently has in Gilead.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Oncology, Food and Drug Administration

Seeking Alpha

Gilead: Rising Short Interest Provides Yet Another Reason To Own The Stock

Its forward P/E is low relative to the market, thus incorporating caution about the sustainability of profits from its hepatitis C franchise.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, CGI Pharmaceuticals, Pharmaceuticals, Pharmasset

Business Journal

Gilead beats back Roche, wins U.K. victory for hepatitis C drug Sovaldi

An arbitration panel ruled Friday that the Foster City-based drug maker's hepatitis C blockbuster Sovaldi did not infringe a 2004 research deal that rival Roche had with Pharmasset Inc. Gilead , led by Chairman and CEO John Martin , bought Pharmasset in 2012 for $11 billion, landing the drug that would become Sovaldi.

Comment?

Related Topix: Startups, Gilead Sciences, Biotech, Medicine, Healthcare Industry, Pharmaceuticals, Pharmasset, Genentech

BioSpace

Gilead Sciences, Inc. Shaky As Achillion Pharmaceuticals, Inc.'s...

Achillion Pharmaceuticals, Inc. today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naA ve genotype 1 chronic hepatitis C virus infection.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Startups, Gilead Sciences, Achillion Pharmaceuticals, Pharmaceuticals

Barron's

Morning Movers: Gannett Gains on Icahn; Nordstrom Drops on Earnings

They're sure going to try. S&P 500 futures have risen 0.2%, while Dow Jones Industrial futures have gained 0.3%.

Comment?

Related Topix: Nordstrom, Retail, Apparel, Estee Lauder Companies, Household Products, Biotech, Medicine, Healthcare Industry, Financial Markets

Thu Aug 14, 2014

Investor's Business Daily

OmniVision, Tata Score New Highs As Market Rallies

Many of the same names extended their highs on Thursday, but a few new ones joined in as the market rallied.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

AmericanBankingNews.com

Gilead Sciences Receives New Coverage from Analysts at FBR Capital Markets

Gilead Sciences traded up 2.53% on Thursday, hitting $96.36. The stock had a trading volume of 12,343,462 shares.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••